Veru Inc. (FMW0)

Overview

Veru Inc. is an oncology biopharmaceutical company dedicated to developing treatments specifically designed for various cancers. Initially established in 1971 and known as The Female Health Company, it rebranded to Veru Inc. in July 2017. With its headquarters in Miami, Florida, Veru Inc. stands out for its combination of developing innovative cancer therapies alongside commercial products aimed at preventive health care. Its portfolio ranges from cancer drug candidates in various stages of clinical trials to commercial products like the FC2 female condom/internal condom, catering to health ministries, government sectors, and nonprofit organizations globally.

Products and Services

• FC2 Female Condom/Internal Condom

Veru Inc.'s commercial product, the FC2 female condom/internal condom, is designed for dual protection against unintended pregnancies and sexually transmitted infections (STIs). This product is distributed to global ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners.

• Enobosarm

An oral selective androgen receptor agonist currently in phase III clinical trial. Enobosarm is being developed for treating AR+ ER+ HER2- metastatic breast cancer, showcasing Veru Inc.'s focus on targeted cancer therapies.

• Sabizabulin

This compound is in phase IIb clinical trial for AR+ ER+ HER2- metastatic breast cancer and in phase III for SARS-CoV-2 subjects at high risk for ARDS. Additionally, it's being tested in a phase III trial for metastatic castration and androgen receptor targeting agent resistant prostate cancer, indicating its versatility in treating both cancer and severe viral infections.

• Enobosarm + Abemaciclib Combination Therapy

A phase III clinical trial underway for AR+ ER+ HER2- metastatic breast cancer. This combination highlights Veru Inc.'s strategy in exploring synergistic effects between different cancer-fighting drugs.

• Sabizabulin + Enobosarm Combination Therapy

An innovative approach combining a targeted cytoskeleton disruptor with a selective androgen receptor agonist. Currently in phase II clinical trial for treating metastatic triple-negative breast cancer, this combination therapy illustrates the company's investment in cutting-edge cancer treatment methods.

• VERU-100

A GnRH antagonist peptide injection in Phase II clinical trial, targeting advanced hormone-sensitive prostate cancer. This product represents Veru Inc.'s venture into hormone-based cancer therapies.

• Zuclomiphene Citrate

Currently in Phase II clinical trial, this compound is being developed to address hot flashes, a common side effect of cancer therapy, demonstrating Veru Inc.'s commitment to improving patients' quality of life during treatment.

• New Drug Formulation for Lower Urinary Tract Symptoms (LUTS)

Veru Inc. is also advancing a novel drug formulation aimed at treating men with lower urinary tract symptoms resulting from an enlarged prostate, further diversifying its portfolio into urological conditions often associated with prostate cancer treatments.